Paul Hastings LLP
We only have limited information for this firm. Consider the following firms which have provided more information:
Paul Hastings LLP houses a broad team which exhibits strength across a broad range of areas, namely investment strategy, fund management, and exits. Fang Pei and Vivian Lam jointly lead the Hong Kong team. Lam is particularly adept at assisting Chinese companies and financial institutions with transactional issues, whilst Pei has deep knowledge of venture capital financings and securities offerings. Neil Torpey left the practice in March 2023.
Legal 500 Editorial commentary
Key clients
- CDH Investments
- Ping An Group
Abbreviated data is displayed for this firm.
Work highlights
- Advised GenScript Biotech Corporation and its subsidiary Probio Technology Limited in Probio’s Series C financing with investments from Legend Capital, Highlight Capital, Hillhouse (Probio’s Series A investor) and other prominent institutional investors.
- Represented GenScript Biotech and its subsidiary Probio Technology Limited in a US$37 m Series B financing from Zhenjiang High-Tech Venture Capital.
Abbreviated data is displayed for this firm.